siRNA delivery: from basics to therapeutic applications
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The chance to selectively intervene and stop the development of any gene-dependent disease in different organs and pathologies makes siRNA an ideal therapeutic agent. However, serious issues should be addressed before the real therapeutic use of siRNA. The poor pharmacokinetic properties of siRNA, its short half-life, its low in vivo stability, its fast elimination by kidney filtration and its low transfection efficiency complicate the use of siRNA as a therapeutic molecule. In this review, we will describe the latest and most advanced approaches and strategies undertaken to address these limitations and improve siRNA delivery and its gene silencing efficacy as well as the prospects for its therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional siRNAs and miRNAs exhibit strand bias
Khvorova, A., Reynolds, A., & Jayasena, S. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00801-8 · Cited by 2,645 · cited 3×
“Some studies (see references in (59, 66, 67)) indicated that the integrity of the 5′- terminus of the antisense strand is the most important requirement needed to trigger the RNAi mechanism.”
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305 · cited 2×
“Diabetic retinopathy is the leading cause of newly diagnosed blindness in the working age (20-74) population in the United States and is the leading cause of vision loss in diabetic retinopathy.”
BackgroundHarper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682 · cited 2×
“In fact, its potential efficacy in the treatment of infections, cancer, neurodegenerative diseases, antiviral diseases, hematological diseases, pain and inherited genetic disorders is likely to lead to several novel medical applications in the near future (see references in (43-47)).”
BackgroundTargeted Delivery of Small Interfering RNA: Approaching Effective Cancer Therapies
Pirollo, K. F., & Chang, E. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5810 · Cited by 121
Cited by
Multifunctional polymeric micelles for delivery of drugs and siRNA
Jhaveri, A. M., & Torchilin, V. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00077 · Cited by 466
“Additional examples for multifunctional siRNA-loaded micelles are given in Table 5 .”
BackgroundInfluentialSelf-citationSpeicher, T., Siegenthaler, B., Bogorad, R. L., Ruppert, R., Petzold, T., Padrissa-Altes, S., Bachofner, M., Anderson, D. G., Koteliansky, V., Fässler, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4862 · Cited by 85
Tomaru, Y., Hasegawa, R., Suzuki, T., Sato, T., Kubosaki, A., Suzuki, M., Kawaji, H., Forrest, A. R. R., Hayashizaki, Y., FANTOM Consortium, et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku567 · Cited by 39
“The siRNA transfection is an ideal strategy for cell reprogramming due to their transient properties in the host cell (28,29).”
Background
Metadata
- Authors
- Torchilin, V.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2013
- Volume
- 18
- Issue
- 1
- Pages
- 58
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/4087
- OpenAlex
- W1963589190
- Cited by
- 46
- References
- 5
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.